폐동맥 고혈압(PAH) 시장 : 제품 유형, 최종 사용자, 지역별(북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카) - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

Persistence Market Research presents an in-depth analysis of the Pulmonary Arterial Hypertension (PAH) Market, offering insights into its intricate dynamics and future trajectory. From market trends to growth catalysts, impediments, and emerging patterns, this report furnishes invaluable statistics and projections spanning from 2024 to 2032.

Key Insights:

• Pulmonary Arterial Hypertension Market Size (2024): USD 8.4 Billion
• Projected Market Value (2032): USD 13.7 Billion
• Global Market Growth Rate (CAGR 2024 to 2032): 7.2%

Pulmonary Arterial Hypertension Market - Report Scope:

The Pulmonary Arterial Hypertension Market encompasses various treatment options, including prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators. This market caters to a wide range of end-users, including hospitals, clinics, and specialty treatment centers, offering advanced therapeutic solutions for managing PAH. Market growth is driven by factors such as advancements in medical research, rising prevalence of PAH, and increasing awareness about the disease and its treatments.

Market Growth Drivers:

The global Pulmonary Arterial Hypertension Market is bolstered by several key growth drivers. Advancements in medical research and the development of novel therapeutic agents enhance treatment efficacy and patient outcomes, driving the adoption of PAH therapies. Moreover, the rising prevalence of PAH, fueled by factors such as genetic predisposition, lifestyle changes, and comorbid conditions, creates significant demand for effective treatment options. Additionally, increasing awareness about PAH and its treatments, along with supportive government initiatives and funding for rare disease research, stimulates market growth and encourages the development of innovative therapies.

Market Restraints:

Despite its promising growth prospects, the Pulmonary Arterial Hypertension Market faces challenges related to high treatment costs, limited patient awareness in developing regions, and stringent regulatory requirements. The high cost of PAH treatments imposes financial burdens on patients and healthcare systems, potentially limiting access to advanced therapies. Furthermore, limited awareness about PAH and its symptoms in developing regions affects early diagnosis and treatment, hindering market expansion. Additionally, stringent regulatory requirements for drug approval and compliance impose compliance burdens on manufacturers, impacting market growth.

Market Opportunities:

The Pulmonary Arterial Hypertension Market presents lucrative growth opportunities driven by technological innovation, strategic collaborations, and market expansion. Emerging trends such as personalized medicine, advanced diagnostic techniques, and combination therapies inspire manufacturers to explore new treatment approaches and improve patient outcomes. Moreover, strategic partnerships, research collaborations, and mergers and acquisitions enable market players to expand their product portfolios, enhance their technical capabilities, and strengthen their market presence in key regions. Furthermore, growing investments in research and development, coupled with increasing government support for rare disease research and treatment, create a conducive environment for market expansion and diversification.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Pulmonary Arterial Hypertension Market globally?
• How are technological advancements and industry trends shaping the evolution of PAH treatments and therapies?
• What are the key challenges and opportunities facing market participants in the PAH segment?
• Which treatment options and geographic regions offer the highest growth potential for PAH manufacturers?
• What strategies are leading companies employing to differentiate their PAH offerings and capture market share in the competitive healthcare landscape?

Competitive Intelligence and Business Strategy:

Leading players in the global Pulmonary Arterial Hypertension Market, including pharmaceutical companies and research institutions, focus on innovation, product differentiation, and market expansion to gain a competitive edge. These companies invest in research and development to develop advanced therapeutic agents, improve treatment efficacy, and explore new applications for PAH therapies. Moreover, strategic collaborations with research institutions, academic partners, and industry associations enable market players to access new technologies, expand their knowledge base, and accelerate product development efforts. Furthermore, emphasis on regulatory compliance, patient-centric initiatives, and corporate social responsibility enhances brand reputation and fosters long-term relationships with customers and stakeholders.

Key Companies Profiled:

• Actelion Pharmaceuticals Ltd (a Janssen Pharmaceutical Company)
• Gilead Sciences, Inc.
• United Therapeutics Corporation
• Bayer AG
• GlaxoSmithKline plc
• Pfizer Inc.
• Novartis International AG
• Arena Pharmaceuticals, Inc.
• Merck & Co., Inc.
• Acceleron Pharma Inc.

Pulmonary Arterial Hypertension Market Research Segmentation:

By Drug Class

• Endothelin Receptor Antagonists
• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators

By Type

• Branded
• Generics

By Route of Administration

• Oral
• Intravenous/ Subcutaneous
• Inhalational

By Region

• North America
• Latin America
• Europe
• APAC
• MEA

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Summary of Statistics
• 1.3. Key Market Characteristics & Attributes
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations

3. Market Risks and Trends Assessment

• 3.1. Risk Assessment
  • 3.1.1. COVID-19 Crisis and Impact on Pulmonary Arterial Hypertension Market
  • 3.1.2. COVID-19 Impact Benchmark with Previous Crisis
  • 3.1.3. Impact on Market Value (US$ Bn)
  • 3.1.4. Assessment by Key Countries
  • 3.1.5. Assessment by Key Market Segments
  • 3.1.6. Action Points and Recommendation for Suppliers
• 3.2. Key Trends Impacting the Market
• 3.3. Formulation and Product Development Trends

4. Market Background

• 4.1. Pulmonary Arterial Hypertension Market, by Key Countries
• 4.2. Pulmonary Arterial Hypertension Market Opportunity Assessment (US$ Bn)
  • 4.2.1. Total Available Market
  • 4.2.2. Serviceable Addressable Market
  • 4.2.3. Serviceable Obtainable Market
• 4.3. Market Scenario Forecast
  • 4.3.1. Demand in optimistic Scenario
  • 4.3.2. Demand in Likely Scenario
  • 4.3.3. Demand in Conservative Scenario
• 4.4. Investment Feasibility Analysis
  • 4.4.1. Investment in Established Markets
    • 4.4.1.1. In Short Term
    • 4.4.1.2. In Long Term
  • 4.4.2. Investment in Emerging Markets
    • 4.4.2.1. In Short Term
    • 4.4.2.2. In Long Term
• 4.5. Forecast Factors - Relevance & Impact
  • 4.5.1. Top Companies Historical Growth
  • 4.5.2. Growth in Automation, By Country
  • 4.5.3. Microneedle Drug Delivery Systems Markets Adoption Rate, By Country
• 4.6. Market Dynamics
  • 4.6.1. Market Driving Factors and Impact Assessment
  • 4.6.2. Prominent Market Challenges and Impact Assessment
  • 4.6.3. Microneedle Drug Delivery Systems Markets Market Opportunities
  • 4.6.4. Prominent Trends in the Global Market & Their Impact Assessment

5. Key Success Factors

• 5.1. Manufacturers' Focus on Low Penetration High Growth Markets
• 5.2. Banking on with Segments High Incremental Opportunity
• 5.3. Peer Benchmarking

6. Global Pulmonary Arterial Hypertension Market Demand Analysis 2019-2023 and Forecast, 2024-2032

• 6.1. Historical Market Analysis, 2019-2023
• 6.2. Current and Future Market Projections, 2024-2032
• 6.3. Y-o-Y Growth Trend Analysis

7. Global Pulmonary Arterial Hypertension Market Value Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032, By Drug Class

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis By Drug Class, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug Class, 2024-2032
  • 8.3.1. Endothelin Receptor Antagonists (ERAs)
  • 8.3.2. PDE-5 inhibitors
  • 8.3.3. Prostacyclin and Prostacyclin Analogs
  • 8.3.4. SGC Stimulators
• 8.4. Market Attractiveness Analysis By Microneedle Drug Delivery Systems

9. Global Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032, By Type

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis By Type, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Type, 2024-2032
  • 9.3.1. Branded
  • 9.3.2. Generics
• 9.4. Market Attractiveness Analysis By Route of Administration

10. Global Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Bn) Analysis By Route of Administration, 2019-2023
• 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Route of Administration, 2024-2032
  • 10.3.1. Oral
  • 10.3.2. Intravenous/ Subcutaneous
  • 10.3.3. Inhalational
• 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032, By Region

• 11.1. Introduction
• 11.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
• 11.3. Current Market Size (US$ Bn) & Analysis and Forecast By Region, 2024-2032
  • 11.3.1. North America
  • 11.3.2. Latin America
  • 11.3.3. Europe
  • 11.3.4. Asia Pacific
  • 11.3.5. Middle East and Africa (MEA)
• 11.4. Market Attractiveness Analysis By Region

12. North America Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

• 12.1. Introduction
• 12.2. Pricing Analysis
• 12.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 12.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2024-2032
  • 12.4.1. By Country
    • 12.4.1.1. U.S.
    • 12.4.1.2. Canada
  • 12.4.2. By Drug Class
  • 12.4.3. By Route of Administration
  • 12.4.4. By Route of Administration
• 12.5. Market Attractiveness Analysis
  • 12.5.1. By Country
  • 12.5.2. By Type
  • 12.5.3. By Route of Administration
  • 12.5.4. By Route of Administration

13. Latin America Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Pricing Analysis
• 13.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2024-2032
  • 13.4.1. By Country
    • 13.4.1.1. Brazil
    • 13.4.1.2. Mexico
    • 13.4.1.3. Rest of Latin America
  • 13.4.2. By Drug Class
  • 13.4.3. By Route of Administration
  • 13.4.4. By Route of Administration
• 13.5. Market Attractiveness Analysis
  • 13.5.1. By Country
  • 13.5.2. By Type
  • 13.5.3. By Route of Administration
  • 13.5.4. By Route of Administration

14. Europe Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Pricing Analysis
• 14.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2024-2032
  • 14.4.1. By Country
    • 14.4.1.1. Germany
    • 14.4.1.2. France
    • 14.4.1.3. U.K.
    • 14.4.1.4. Italy
    • 14.4.1.5. Spain
    • 14.4.1.6. Russia
    • 14.4.1.7. Rest of Europe
  • 14.4.2. By Drug Class
  • 14.4.3. By Route of Administration
  • 14.4.4. By Route of Administration
• 14.5. Market Attractiveness Analysis
  • 14.5.1. By Country
  • 14.5.2. By Type
  • 14.5.3. By Route of Administration
  • 14.5.4. By Route of Administration

15. Asia Pacific Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
• 15.2. Pricing Analysis
• 15.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2024-2032
  • 15.4.1. By Country
    • 15.4.1.1. China
    • 15.4.1.2. Japan
    • 15.4.1.3. South Korea
    • 15.4.1.4. India
    • 15.4.1.5. Australia
    • 15.4.1.6. Rest of Asia Pacific
  • 15.4.2. By Drug Class
  • 15.4.3. By Route of Administration
  • 15.4.4. By Route of Administration
• 15.5. Market Attractiveness Analysis
  • 15.5.1. By Country
  • 15.5.2. By Type
  • 15.5.3. By Route of Administration
  • 15.5.4. By Route of Administration

16. Middle East and Africa Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

• 16.1. Introduction
• 16.2. Pricing Analysis
• 16.3. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.4. Market Size (US$ Bn) & Forecast By Market Taxonomy, 2024-2032
  • 16.4.1. By Country
    • 16.4.1.1. Saudi Arabia
    • 16.4.1.2. South Africa
    • 16.4.1.3. Israel
    • 16.4.1.4. UAE
    • 16.4.1.5. Rest of Middle East and Africa
  • 16.4.2. By Drug Class
  • 16.4.3. By Route of Administration
  • 16.4.4. By Route of Administration
• 16.5. Market Attractiveness Analysis
  • 16.5.1. By Country
  • 16.5.2. By Type
  • 16.5.3. By Route of Administration
  • 16.5.4. By Route of Administration

17. Key Countries Pulmonary Arterial Hypertension Market Analysis 2019-2023 and Forecast 2024-2032

• 17.1. Introduction
  • 17.1.1. Market Value Proportion Analysis, By Key Countries
  • 17.1.2. Global Vs. Country Growth Comparison
• 17.2. US Pulmonary Arterial Hypertension Market Analysis
  • 17.2.1. Value Proportion Analysis by Market Taxonomy
  • 17.2.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.2.2.1. By Drug Class
    • 17.2.2.2. By Route of Administration
    • 17.2.2.3. By Route of Administration
• 17.3. Canada Pulmonary Arterial Hypertension Market Analysis
  • 17.3.1. Value Proportion Analysis by Market Taxonomy
  • 17.3.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.3.2.1. By Type
    • 17.3.2.2. By Route of Administration
    • 17.3.2.3. By Route of Administration
• 17.4. Mexico Pulmonary Arterial Hypertension Market Analysis
  • 17.4.1. Value Proportion Analysis by Market Taxonomy
  • 17.4.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.4.2.1. By Drug Class
    • 17.4.2.2. By Route of Administration
    • 17.4.2.3. By Route of Administration
• 17.5. Brazil Pulmonary Arterial Hypertension Market Analysis
  • 17.5.1. Value Proportion Analysis by Market Taxonomy
  • 17.5.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.5.2.1. By Type
    • 17.5.2.2. By Route of Administration
    • 17.5.2.3. By Route of Administration
• 17.6. Germany Pulmonary Arterial Hypertension Market Analysis
  • 17.6.1. Value Proportion Analysis by Market Taxonomy
  • 17.6.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.6.2.1. By Drug Class
    • 17.6.2.2. By Route of Administration
    • 17.6.2.3. By Route of Administration
• 17.7. France Pulmonary Arterial Hypertension Market Analysis
  • 17.7.1. Value Proportion Analysis by Market Taxonomy
  • 17.7.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.7.2.1. By Drug Class
    • 17.7.2.2. By Route of Administration
    • 17.7.2.3. By Route of Administration
• 17.8. Italy Pulmonary Arterial Hypertension Market Analysis
  • 17.8.1. Value Proportion Analysis by Market Taxonomy
  • 17.8.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.8.2.1. By Drug Class
    • 17.8.2.2. By Route of Administration
    • 17.8.2.3. By Route of Administration
• 17.9. India Pulmonary Arterial Hypertension Market Analysis
  • 17.9.1. Value Proportion Analysis by Market Taxonomy
  • 17.9.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.9.2.1. By Drug Class
    • 17.9.2.2. By Route of Administration
    • 17.9.2.3. By Route of Administration
• 17.10. UK Pulmonary Arterial Hypertension Market Analysis
  • 17.10.1. Value Proportion Analysis by Market Taxonomy
  • 17.10.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.10.2.1. By Type
    • 17.10.2.2. By Route of Administration
    • 17.10.2.3. By Route of Administration
• 17.11. Australia Pulmonary Arterial Hypertension Market Analysis
  • 17.11.1. Value Proportion Analysis by Market Taxonomy
  • 17.11.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.11.2.1. By Drug Class
    • 17.11.2.2. By Route of Administration
    • 17.11.2.3. By Route of Administration
• 17.12. China Pulmonary Arterial Hypertension Market Analysis
  • 17.12.1. Value Proportion Analysis by Market Taxonomy
  • 17.12.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.12.2.1. By Drug Class
    • 17.12.2.2. By Route of Administration
    • 17.12.2.3. By Route of Administration
• 17.13. Japan Pulmonary Arterial Hypertension Market Analysis
  • 17.13.1. Value Proportion Analysis by Market Taxonomy
  • 17.13.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.13.2.1. By Drug Class
    • 17.13.2.2. By Route of Administration
    • 17.13.2.3. By Route of Administration
• 17.14. South Korea Pulmonary Arterial Hypertension Market Analysis
  • 17.14.1. Value Proportion Analysis by Market Taxonomy
  • 17.14.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.14.2.1. By Drug Class
    • 17.14.2.2. By Route of Administration
    • 17.14.2.3. By Route of Administration
• 17.15. Israel Pulmonary Arterial Hypertension Market Analysis
  • 17.15.1. Value Proportion Analysis by Market Taxonomy
  • 17.15.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.15.2.1. By Drug Class
    • 17.15.2.2. By Route of Administration
    • 17.15.2.3. By Route of Administration
• 17.16. South Africa Pulmonary Arterial Hypertension Market Analysis
  • 17.16.1. Value Proportion Analysis by Market Taxonomy
  • 17.16.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.16.2.1. By Drug Class
    • 17.16.2.2. By Route of Administration
    • 17.16.2.3. By Route of Administration
• 17.17. UAE Pulmonary Arterial Hypertension Market Analysis
  • 17.17.1. Value Proportion Analysis by Market Taxonomy
  • 17.17.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.17.2.1. By Drug Class
    • 17.17.2.2. By Route of Administration
    • 17.17.2.3. By Route of Administration
• 17.18. Spain Pulmonary Arterial Hypertension Market Analysis
  • 17.18.1. Value Proportion Analysis by Market Taxonomy
  • 17.18.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.18.2.1. By Drug Class
    • 17.18.2.2. By Route of Administration
    • 17.18.2.3. By Route of Administration
• 17.19. Russia Pulmonary Arterial Hypertension Market Analysis
  • 17.19.1. Value Proportion Analysis by Market Taxonomy
  • 17.19.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.19.2.1. By Drug Class
    • 17.19.2.2. By Route of Administration
    • 17.19.2.3. By Route of Administration
• 17.20. Saudi Arabia Pulmonary Arterial Hypertension Market Analysis
  • 17.20.1. Value Proportion Analysis by Market Taxonomy
  • 17.20.2. Value & Analysis and Forecast by Market Taxonomy, 2024-2032
    • 17.20.2.1. By Drug Class
    • 17.20.2.2. By Route of Administration
    • 17.20.2.3. By Route of Administration
• 17.21. Competition Landscape and Player Concentration in the Country

18. Market Structure Analysis

• 18.1. Market Analysis by Tier of Companies
• 18.2. Market Concentration
• 18.3. Market Share Analysis of Top Players
• 18.4. Market Presence Analysis
  • 18.4.1. By Regional footprint of Players
  • 18.4.2. Product footprint by Players

19. Competition Analysis

• 19.1. Competition Dashboard
• 19.2. Competition Benchmarking
• 19.3. Competition Deep Dive
  • 19.3.1. United Therapeutics Corporation
    • 19.3.1.1. Overview
    • 19.3.1.2. Product Portfolio
    • 19.3.1.3. Sales Footprint
    • 19.3.1.4. Strategy Overview
  • 19.3.2. Bayer
    • 19.3.2.1. Overview
    • 19.3.2.2. Product Portfolio
    • 19.3.2.3. Sales Footprint
    • 19.3.2.4. Strategy Overview
  • 19.3.3. Johnson & Johnson
    • 19.3.3.1. Overview
    • 19.3.3.2. Product Portfolio
    • 19.3.3.3. Sales Footprint
    • 19.3.3.4. Strategy Overview
  • 19.3.4. Novartis
    • 19.3.4.1. Overview
    • 19.3.4.2. Product Portfolio
    • 19.3.4.3. Sales Footprint
    • 19.3.4.4. Strategy Overview
  • 19.3.5. Lupin Pharmaceuticals
    • 19.3.5.1. Overview
    • 19.3.5.2. Product Portfolio
    • 19.3.5.3. Sales Footprint
    • 19.3.5.4. Strategy Overview
  • 19.3.6. Viatris Inc.
    • 19.3.6.1. Overview
    • 19.3.6.2. Product Portfolio
    • 19.3.6.3. Sales Footprint
    • 19.3.6.4. Strategy Overview
  • 19.3.7. Sun Pharmaceutical Industries, Inc.
    • 19.3.7.1. Overview
    • 19.3.7.2. Product Portfolio
    • 19.3.7.3. Sales Footprint
    • 19.3.7.4. Strategy Overview
  • 19.3.8. Teva Pharmaceutical Industries Ltd.
    • 19.3.8.1. Overview
    • 19.3.8.2. Product Portfolio
    • 19.3.8.3. Sales Footprint
    • 19.3.8.4. Strategy Overview

20. Assumptions and Acronyms Used

21. Research Methodology